Therapeutic benefit of radiotherapy in huge (≥10 cm) unresectable hepatocellular carcinoma

Liver International

Volumn 34, Issue 5, 2014, Pages 784-794

  Kim, Kyung Hwan ^a   Kim, Mi Sun ^a   Chang, Jee Suk ^a   Han, Kwang Hyub ^a   Kim, Do Young ^a   Seong, Jinsil ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Huge hepatocellular carcinoma; Radiotherapy; Survival; Unresectable

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ANTIBIOTIC AGENT; ASPARTATE AMINOTRANSFERASE; CARBOPLATIN; CISPLATIN; DOXORUBICIN; FLUOROURACIL; SORAFENIB;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ANTIBIOTIC THERAPY; ARTICLE; ASCITES; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CHEMOEMBOLIZATION; CHEMORADIOTHERAPY; CONSERVATIVE TREATMENT; CONTROLLED STUDY; FEMALE; FOLLOW UP; GASTROENTERITIS; HEPATIC ARTERIAL INFUSION CHEMOTHERAPY; HEPATOMEGALY; HUMAN; HYPERBILIRUBINEMIA; HYPERTRANSAMINASEMIA; LEUKOPENIA; LIVER ABSCESS; LIVER CELL CARCINOMA; LIVER FUNCTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MUCOSA INFLAMMATION; MULTIMODALITY CANCER THERAPY; NAUSEA AND VOMITING; OVERALL SURVIVAL; PEPTIC ULCER; PROGRESSION FREE SURVIVAL; RADIATION DOSE; SIDE EFFECT; STOMACH PERFORATION; THROMBOCYTOPENIA; TOMOTHERAPY; TRANSARTERIAL CHEMOEMBOLIZATION; TREATMENT DURATION; CARCINOMA, HEPATOCELLULAR; EPIDEMIOLOGY; LIVER; LIVER NEOPLASMS; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; RADIOTHERAPY; RETROSPECTIVE STUDY; SOUTH KOREA; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; LIVER; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; RADIOTHERAPY; REPUBLIC OF KOREA; RETROSPECTIVE STUDIES;

EID: 84897959514     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12436     Document Type: Article

References (38)

1. Sherman M. Epidemiology of hepatocellular carcinoma. Oncology 2010; 78(Suppl 1): 7-10.
2. Yeh CN, Lee WC, Chen MF. Hepatic resection and prognosis for patients with hepatocellular carcinoma larger than 10 cm: two decades of experience at Chang Gung memorial hospital. Ann Surg Oncol 2003; 10: 1070-6.
3. Poon RT, Fan ST, Wong J. Selection criteria for hepatic resection in patients with large hepatocellular carcinoma larger than 10 cm in diameter. J Am Coll Surg 2002; 194: 592-602.
4. Choi GH, Han DH, Kim DH, et al. Outcome after curative resection for a huge (>or=10 cm) hepatocellular carcinoma and prognostic significance of gross tumor classification. Am J Surg 2009; 198: 693-701.
5. Shrager B, Jibara GA, Tabrizian P, et al. Resection of large hepatocellular carcinoma (>/=10 cm): a unique western perspective. J Surg Oncol 2013; 107: 111-7.
6. Ariizumi S, Kotera Y, Takahashi Y, Katagiri S, Yamamoto M. Impact of hepatectomy for huge solitary hepatocellular carcinoma. J Surg Oncol 2013; 107: 408-13.
7. Pandey D, Lee KH, Wai CT, Wagholikar G, Tan KC. Long term outcome and prognostic factors for large hepatocellular carcinoma (10 cm or more) after surgical resection. Ann Surg Oncol 2007; 14: 2817-23.
8. Liau KH, Ruo L, Shia J, et al. Outcome of partial hepatectomy for large (> 10 cm) hepatocellular carcinoma. Cancer 2005; 104: 1948-55.
9. Hawkins MA, Dawson LA. Radiation therapy for hepatocellular carcinoma: from palliation to cure. Cancer 2006; 106: 1653-63.
10. Chia-Hsien Cheng J, Chuang VP, Cheng SH, et al. Unresectable hepatocellular carcinoma treated with radiotherapy and/or chemoembolization. Int J Cancer 2001; 96: 243-52.
11. European Association For The Study Of The L, European Organisation For R, Treatment Of C. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56: 908-43.
12. Bruix J, Sherman M, American Association for the Study of Liver D. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-2.
13. Klein J, Dawson LA. Hepatocellular carcinoma radiation therapy: review of evidence and future opportunities. Int J Radiat Oncol Biol Phys 2013; 87: 22-32.
14. Vogl TJ, Trapp M, Schroeder H, et al. Transarterial chemoembolization for hepatocellular carcinoma: volumetric and morphologic CT criteria for assessment of prognosis and therapeutic success-results from a liver transplantation center. Radiology 2000; 214: 349-57.
15. Rixe O, Fojo T. Is cell death a critical end point for anticancer therapies or is cytostasis sufficient? Clin Cancer Res 2007; 13: 7280-7.
16. Seong J, Park HC, Han KH, Chon CY. Clinical results and prognostic factors in radiotherapy for unresectable hepatocellular carcinoma: a retrospective study of 158 patients. Int J Radiat Oncol Biol Phys 2003; 55: 329-36.
17. Seong J, Park HC, Han KH, et al. Local radiotherapy for unresectable hepatocellular carcinoma patients who failed with transcatheter arterial chemoembolization. Int J Radiat Oncol Biol Phys 2000; 47: 1331-5.
18. Meng MB, Cui YL, Lu Y, et al. Transcatheter arterial chemoembolization in combination with radiotherapy for unresectable hepatocellular carcinoma: a systematic review and meta-analysis. Radiother Oncol 2009; 92: 184-94.
19. Shim SJ, Seong J, Han KH, et al. Local radiotherapy as a complement to incomplete transcatheter arterial chemoembolization in locally advanced hepatocellular carcinoma. Liver Int 2005; 25: 1189-96.
20. Han KH, Seong J, Kim JK, et al. Pilot clinical trial of localized concurrent chemoradiation therapy for locally advanced hepatocellular carcinoma with portal vein thrombosis. Cancer 2008; 113: 995-1003.
21. Koom WS, Seong J, Han KH, Lee do Y, Lee JT. Is local radiotherapy still valuable for patients with multiple intrahepatic hepatocellular carcinomas? Int J Radiat Oncol Biol Phys 2010; 77: 1433-40.
22. Park MS, Kim SU, Park JY, et al. Combination treatment of localized concurrent chemoradiation therapy and transarterial chemoembolization in locally advanced hepatocellular carcinoma with intrahepatic metastasis. Cancer Chemother Pharmacol 2013; 71: 165-73.
23. Korean Liver Cancer Study, G, National Cancer Center K. Practice guidelines for management of hepatocellular carcinoma 2009]. Korean J Hepatol 2009; 15: 391-423.
24. Park JY, Ahn SH, Yoon YJ, et al. Repetitive short-course hepatic arterial infusion chemotherapy with high-dose 5-fluorouracil and cisplatin in patients with advanced hepatocellular carcinoma. Cancer 2007; 110: 129-37.
25. Chon YE, Seong J, Kim BK, et al. Gastroduodenal complications after concurrent chemoradiation therapy in patients with hepatocellular carcinoma: endoscopic findings and risk factors. Int J Radiat Oncol Biol Phys 2011; 81: 1343-51.
26. Pan CC, Kavanagh BD, Dawson LA, et al. Radiation-associated liver injury. Int J Radiat Oncol Biol Phys 2010; 76: S94-100.
27. Pawlik TM, Delman KA, Vauthey JN, et al. Tumor size predicts vascular invasion and histologic grade: implications for selection of surgical treatment for hepatocellular carcinoma. Liver Transpl 2005; 11: 1086-92.
28. Mazzaferro V, Llovet JM, Miceli R, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 2009; 10: 35-43.
29. Park HC, Seong J, Han KH, et al. Dose-response relationship in local radiotherapy for hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2002; 54: 150-5.
30. Kim DY, Park W, Lim DH, et al. Three-dimensional conformal radiotherapy for portal vein thrombosis of hepatocellular carcinoma. Cancer 2005; 103: 2419-26.
31. Park W, Lim DH, Paik SW, et al. Local radiotherapy for patients with unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2005; 61: 1143-50.
32. Cha H, Yoon HI, Lee IJ, et al. Clinical factors related to recurrence after hepatic arterial concurrent chemoradiotherapy for advanced but liver-confined hepatocellular carcinoma. J Radiat Res 2013; 54: 1069-77.
33. The Cancer of the Liver Italian Program (CLIP) investigators. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients. Hepatology 1998; 28: 751-5.
34. The Liver Cancer Study Group of Japan. Predictive factors for long term prognosis after partial hepatectomy for patients with hepatocellular carcinoma in Japan. Cancer 1994; 74: 2772-80.
35. Dawson LA, Normolle D, Balter JM, et al. Analysis of radiation-induced liver disease using the Lyman NTCP model. Int J Radiat Oncol Biol Phys 2002; 53: 810-21.
36. Liang SX, Zhu XD, Xu ZY, et al. Radiation-induced liver disease in three-dimensional conformal radiation therapy for primary liver carcinoma: the risk factors and hepatic radiation tolerance. Int J Radiat Oncol Biol Phys 2006; 65: 426-34.
37. Cheng JC, Wu JK, Lee PC, et al. Biologic susceptibility of hepatocellular carcinoma patients treated with radiotherapy to radiation-induced liver disease. Int J Radiat Oncol Biol Phys 2004; 60: 1502-9.
38. Kim TH, Kim DY, Park JW, et al. Dose-volumetric parameters predicting radiation-induced hepatic toxicity in unresectable hepatocellular carcinoma patients treated with three-dimensional conformal radiotherapy. Int J Radiat Oncol Biol Phys 2007; 67: 225-31.